Meanwhile, the BSE Sensex was down 234.93 points, or 1.31% to 17,688.64

On BSE, 7.87 lakh shares were traded in the counter as against average daily volume of 5.55 lakh shares in the past one quarter.

The stock hit a high of Rs 185.25 and a low of Rs 173.20 so far during the day. The stock had hit a 52-week low of Rs 112.25 on 19 December 2011. The stock had hit a 52-week high of Rs 324.65 on 4 April 2011.

The stock outperformed the market over the past one month till 24 February 2012, rising 6.58% compared with the Sensex's 5.46% gain. The scrip had also outperformed the market in past one quarter, advancing 21.42% as against Sensex's 13.02% gain

The mid-cap pharmaceutical company has an equity capital of Rs 70.44 crore. Face value per share is Rs 10.

Reacting to the report of foreign currency convertible bonds (FCCB) repayment, a company spokesperson was quoted as saying that Orchid Chemicals & Pharmaceuticals will inform about if something of this nature happens.

The company had said in December 2011 that it had received $100 million through overseas borrowing to redeem its outstanding FCCB. The company had floated the FCCBs in 2007 seeking funds for capacity expansion among other purposes.

On a consolidated basis, Orchid Chemicals & Pharmaceuticals' reported net loss of Rs 11.07 crore in Q3 December 2011 compared with net profit of Rs 56.62 crore in Q3 December 2010. Net sales rose 4.2% to Rs 482.10 crore in Q3 December 2011 over Q3 December 2010.

Orchid Chemicals & Pharmaceuticals is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk activities, formulations and nutraceuticals.